Sign inJoin waitlistJoin the waitlist

Paolo Strati

Program Director · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Internal Medicine
Mayo Clinic
2014–2016
Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2012–2014
Queen Mary University
2014
Vita-Salute San Raffaele University
2008–2012
Doctor of Medicine
2004–2008

Research

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Nature Medicine · 2020 · 536 citations
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Nature Medicine · 2023 · 216 citations
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
Cell · 2022 · 216 citations

Sattva Neelapu
69 papers
Jason Westin
57 papers
Loretta Nastoupil
56 papers
Sairah Ahmed
53 papers
Ranjit Nair
47 papers
Luis Fayad
44 papers
Christopher Flowers
43 papers
RS
Raphael Steiner
37 papers · 23 as a fellow
Swaminathan Iyer
32 papers
Hun Lee
30 papers · 3 as a resident
Chelsea Pinnix
27 papers
Elizabeth Shpall
23 papers

Grants

Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-Cell Lymphoma
National Cancer Institute · R21
Contact PI · $378.7K · University of Tx Md Anderson Can Ctr
2021–2023

Clinical trials

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2028
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2023–2028
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2022–2030
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2021–2028